Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial-Reference-Cited by-同舟云学术

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Published:2014-10-14 Issue:24 Volume:20 Page:6398-6405
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Galimberti Sara,Luminari Stefano,Ciabatti Elena,Grassi Susanna,Guerrini Francesca,Dondi Alessandra,Marcheselli Luigi,Ladetto Marco,Piccaluga Pier Paolo,Gazzola Anna,Mannu Claudia,Monitillo Luigia,Mantoan Barbara,Del Giudice Ilaria,Della Starza Irene,Cavalli Marzia,Arcaini Luca,Tucci Alessandra,Palumbo Giuseppe Alberto,Rigacci Luigi,Pulsoni Alessandro,Vitolo Umberto,Boccomini Carola,Vallisa Daniele,Bertoldero Giovanni,Gaidano Gianluca,Musto Pellegrino,Petrini Mario,Federico Massimo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis;British Journal of Haematology;2024-04-04

3. Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze;HemaSphere;2024-01

4. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study;Journal of Clinical Oncology;2023-12-14

5. Measurable Residual Disease Monitoring in Lymphoma;Current Hematologic Malignancy Reports;2023-11-06